Phase Ib Dose-Escalation Study of the Akt Inhibitor Ipatasertib (Ipat) with Paclitaxel (P) in Patients (Pts) with Advanced Solid Tumors
نویسندگان
چکیده
منابع مشابه
First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors.
PURPOSE A phase I study was conducted with the primary objective of determining the maximum tolerated dose (MTD) of AUY922 in patients with advanced solid tumors. Secondary objectives included characterization of the safety, pharmacokinetic, and pharmacodynamic profiles. PATIENTS AND METHODS Patients with advanced solid tumors received 1-hour i.v. infusions of AUY922 once a week in a 28-day c...
متن کاملPhase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors
Veliparib (ABT-888) is a potent, orally bioavailable poly(ADP-ribose) polymerase-1 and -2 inhibitor. This phase 1 study evaluated the tolerability, pharmacokinetic profile, safety, and preliminary antitumor activity of single-agent veliparib in Japanese patients with advanced solid tumors. Eligible patients were assigned to treatment with veliparib at 200 or 400 mg dose; veliparib was self-admi...
متن کاملPhase I Dose‐Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
LESSONS LEARNED Ramucirumab was well tolerated in Chinese patients with advanced solid tumors, and adverse events were manageable in this study.Pharmacokinetics characteristics in Chinese patients were similar to those in other populations. Immunogenicity was not detected.No efficacy conclusion could be drawn, and further randomized studies are warranted. BACKGROUND This single-arm, nonrandom...
متن کاملPhase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.
PURPOSE To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and recommended phase II dose of dasatinib in metastatic solid tumors refractory to standard therapies or for which no effective standard therapy exists. EXPERIMENTAL DESIGN In this phase I, open-label, dose-escalation study, patients received 35 to 160 mg of dasatinib twice daily in 28-day cycles either every 12 h...
متن کاملPhase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors.
PURPOSE E7080, an oral multitargeted receptor tyrosine kinase inhibitor, has antiangiogenic and antitumor activity. This Phase I study investigated maximum tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK), pharmacodynamics (PD), and efficacy in patients with advanced solid tumors. EXPERIMENTAL DESIGN In this sequential, dose-escalation, open-label study E7080 was admi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2014
ISSN: 0923-7534
DOI: 10.1093/annonc/mdu331.6